MRC1 and colorectal carcinoma: Indeed, adjuvant fluoropyrimidine monotherapy seems to show limited benefit in MMR-deficient (dMMR)/MSI CRC, and, if adjuvant treatment is decided upon (mostly for some high-risk stage II and stage III CRCs, though there is no agreement between American and European guidelines), this should be a combination of fluoropyrimidine and oxaliplatin.